Register for our free email digests:
Sequana Medical AG
www.sequanamedical.com
Latest From Sequana Medical AG
Sequana Encouraged By First-In-Human Single Dose DSR study
Sequana Medical has reported results from the first-in-human single-dose direct sodium removal (DSR) proof-of-concept study for volume overload due to heart failure.
Sequana Medical Launches Belgian IPO
Sequana Medical has launched an IPO on Euronext Brussels a few days after the US FDA granted a breakthrough device designation to Sequana’s alfapump for liver ascites.
Sequana Medical Pumped About NASH's Market Potential
Following a fresh injection of funding, Sequana Medical is gearing up to grow its European business and begin a pivotal US study for alfapump, its implantable, automated pump for the continual removal of ascites. The Belgian company is positioning itself as a key player in the growing liver disease treatment market.
Execs On The Move, August 2016
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Company Information
- Industry
-
Medical Devices
- Implantable Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
- Therapeutic Areas
- Non-Specific
- Alias(es)
- Ownership
- Private
- Headquarters
-
Worldwide
-
Europe
-
Western Europe
-
Switzerland
-
Switzerland
-
Western Europe
-
Europe
- Parent & Subsidiaries
- Sequana Medical AG
- Senior Management
-
Noel L Johnson, PhD, Pres. & CEO
Ian Crosbie, CFO
Stephen J McGill, Global VP, Sales & Mktg.
Edouard Fonck, PhD, Dir., BD
Steve Whittaker, VP, Cliin. & Reg. Affairs - Contact Info
-
Sequana Medical AG
Phone: 44 403 55 00
Technoparkstrasse 1, Bldg. Darwin
2nd. Fl.
Zurich, 8005
Switzerland
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice